Daraxonrasib pill shows promise against metastatic pancreatic cancer

At the ASCO 2026 oncology conference, researchers unveiled daraxonrasib, an oral medication that targets the KRAS mutation driving most pancreatic cancers. The drug blocks all three KRAS‑mediated mechanisms, a breakthrough that previously limited the effectiveness of therapies. Phase III trial results presented showed that in patients with advanced, metastatic pancreatic cancer, the proportion surviving beyond five years rose to roughly 9‑10 %, compared with less than 10 % historically for this disease stage. The study highlighted the drug’s ability to suppress tumor growth by inhibiting the mutated K‑Ras protein, which is essential for cancer progression and resistance to treatment. While not a cure, experts said the findings represent a significant step forward for a cancer that has long evaded effective therapy.

The announcement generated strong applause from the conference audience, reflecting optimism that daraxonrasib could soon move toward regulatory approval and broader clinical use, potentially improving outcomes for patients worldwide.